Codexis, Inc.
Financials
Valuation Metrics
Codexis, Inc.'s Market Cap is $114M. At end of 2025 it was $147M. Ranked #3040 of 3,116 in US market (top 98%), #1405 of 1,472 on NASDAQ (top 95%), #255 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 96%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $114M | US#3,040/3,116 Sec#255/265 |
| Revenue | $78M | US#2,708/3,116 Sec#133/265 |
| Net Income | $-31M | US—/3,116 Sec—/265 |
| Total Assets | $120M | US#3,038/3,116 Sec#257/265 |
| Net Assets | $33M | US#2,869/3,116 Sec#228/265 |
| Employees | 146 | US#2,539/3,116 Sec#145/265 |
| Value | ||
| P/B | 3.46x | US#2,048/3,116 Sec#125/265 |
| P/S | 1.47x | US#1,142/3,116 Sec#25/265 |
| FCF Yield | -10.69% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -93.22% | US#2,772/3,116 Sec#198/265 |
| ROA | -25.59% | US#2,847/3,116 Sec#146/265 |
| Op. Margin | -31.23% | US#2,616/3,116 Sec#103/265 |
| Revenue Growth | 35.89% | US#338/3,116 Sec#54/265 |
| Financial Health | ||
| Debt Ratio | 264.27% | US#2,000/3,116 Sec#205/265 |
| Total Debt | $73M | US#2,515/3,116 Sec#138/265 |
| FCF | $-12M | US#2,380/3,116 Sec#90/265 |
| Cash | $27M | US#2,777/3,116 Sec#246/265 |
| Current Ratio | 3.06x | US#755/3,116 Sec#186/265 |
| Performance | ||
| 1Y Return | -56.12% | US#2,879/3,116 Sec#238/265 |
| 1M Return | -23.53% | US#2,553/3,116 Sec#190/265 |
| From 52W High | -65.10% | US#2,854/3,116 Sec#226/265 |
| 1Y MDD | -63.51% | US#2,695/3,116 Sec#200/265 |
| Trading | ||
| Volume | 1,078,451 shares | US#1,585/3,116 Sec#159/265 |
| Trading Value | $1M | US#3,011/3,116 Sec#257/265 |
| Per Share | ||
| EPS | $-0.28 | US—/3,116 Sec—/265 |
| BPS | $0.30 | US#2,768/3,116 Sec#223/265 |
Company Info
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.